Copyright Reports & Markets. All rights reserved.

Global C-MET / HGF Inhibitors Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 C-MET / HGF Inhibitors Market Overview

      • 1.1 Product Overview and Scope of C-MET / HGF Inhibitors
      • 1.2 C-MET / HGF Inhibitors Segment by Type
        • 1.2.1 Global C-MET / HGF Inhibitors Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 C-Met Biologic Inhibitors
        • 1.2.3 Small Molecule C-Met Inhibitors
        • 1.2.4 HGF Antagonist Antibodies
        • 1.2.5 C-Met Antagonist Antibodies(MetMAb)
        • 1.2.6 HGF Kringle Variant Antagonists
      • 1.3 C-MET / HGF Inhibitors Segment by Application
        • 1.3.1 C-MET / HGF Inhibitors Consumption Comparison by Application (2014-2025)
        • 1.3.2 Hospital Pharmacies
        • 1.3.3 Retail Pharmacies
        • 1.3.4 Drug Stores
        • 1.3.5 Online Sales
      • 1.4 Global C-MET / HGF Inhibitors Market by Region
        • 1.4.1 Global C-MET / HGF Inhibitors Market Size Region
        • 1.4.2 North America Status and Prospect (2014-2025)
        • 1.4.3 Europe Status and Prospect (2014-2025)
        • 1.4.4 China Status and Prospect (2014-2025)
        • 1.4.5 Japan Status and Prospect (2014-2025)
      • 1.5 Global C-MET / HGF Inhibitors Market Size
        • 1.5.1 Global C-MET / HGF Inhibitors Revenue (2014-2025)
        • 1.5.2 Global C-MET / HGF Inhibitors Production (2014-2025)

      2 Global C-MET / HGF Inhibitors Market Competition by Manufacturers

      • 2.1 Global C-MET / HGF Inhibitors Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global C-MET / HGF Inhibitors Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global C-MET / HGF Inhibitors Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers C-MET / HGF Inhibitors Production Sites, Area Served, Product Types
      • 2.5 C-MET / HGF Inhibitors Market Competitive Situation and Trends
        • 2.5.1 C-MET / HGF Inhibitors Market Concentration Rate
        • 2.5.2 C-MET / HGF Inhibitors Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global C-MET / HGF Inhibitors Production Market Share by Regions

      • 3.1 Global C-MET / HGF Inhibitors Production Market Share by Regions
      • 3.2 Global C-MET / HGF Inhibitors Revenue Market Share by Regions (2014-2019)
      • 3.3 Global C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America C-MET / HGF Inhibitors Production
        • 3.4.1 North America C-MET / HGF Inhibitors Production Growth Rate (2014-2019)
        • 3.4.2 North America C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe C-MET / HGF Inhibitors Production
        • 3.5.1 Europe C-MET / HGF Inhibitors Production Growth Rate (2014-2019)
        • 3.5.2 Europe C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China C-MET / HGF Inhibitors Production (2014-2019)
        • 3.6.1 China C-MET / HGF Inhibitors Production Growth Rate (2014-2019)
        • 3.6.2 China C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan C-MET / HGF Inhibitors Production (2014-2019)
        • 3.7.1 Japan C-MET / HGF Inhibitors Production Growth Rate (2014-2019)
        • 3.7.2 Japan C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global C-MET / HGF Inhibitors Consumption by Regions

      • 4.1 Global C-MET / HGF Inhibitors Consumption by Regions
      • 4.2 North America C-MET / HGF Inhibitors Consumption (2014-2019)
      • 4.3 Europe C-MET / HGF Inhibitors Consumption (2014-2019)
      • 4.4 China C-MET / HGF Inhibitors Consumption (2014-2019)
      • 4.5 Japan C-MET / HGF Inhibitors Consumption (2014-2019)

      5 Global C-MET / HGF Inhibitors Production, Revenue, Price Trend by Type

      • 5.1 Global C-MET / HGF Inhibitors Production Market Share by Type (2014-2019)
      • 5.2 Global C-MET / HGF Inhibitors Revenue Market Share by Type (2014-2019)
      • 5.3 Global C-MET / HGF Inhibitors Price by Type (2014-2019)
      • 5.4 Global C-MET / HGF Inhibitors Production Growth by Type (2014-2019)

      6 Global C-MET / HGF Inhibitors Market Analysis by Applications

      • 6.1 Global C-MET / HGF Inhibitors Consumption Market Share by Application (2014-2019)
      • 6.2 Global C-MET / HGF Inhibitors Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in C-MET / HGF Inhibitors Business

      • 7.1 Abxign
        • 7.1.1 Abxign C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.1.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.1.3 Abxign C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Abbott Laboratories
        • 7.2.1 Abbott Laboratories C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.2.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.2.3 Abbott Laboratories C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Amgen
        • 7.3.1 Amgen C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.3.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.3.3 Amgen C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 ArQule
        • 7.4.1 ArQule C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.4.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.4.3 ArQule C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Astex Therapeutics
        • 7.5.1 Astex Therapeutics C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.5.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.5.3 Astex Therapeutics C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 AVEO Pharmaceuticals
        • 7.6.1 AVEO Pharmaceuticals C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.6.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.6.3 AVEO Pharmaceuticals C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Bristol-Myers Squibb(BMS)
        • 7.7.1 Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.7.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.7.3 Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Chroma Therapeutics
        • 7.8.1 Chroma Therapeutics C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.8.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.8.3 Chroma Therapeutics C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 Daiichi Sankyo
        • 7.9.1 Daiichi Sankyo C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.9.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.9.3 Daiichi Sankyo C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 Deciphera Pharmaceuticals
        • 7.10.1 Deciphera Pharmaceuticals C-MET / HGF Inhibitors Production Sites and Area Served
        • 7.10.2 C-MET / HGF Inhibitors Product Introduction, Application and Specification
        • 7.10.3 Deciphera Pharmaceuticals C-MET / HGF Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 Eisai
      • 7.12 Eli Lilly
      • 7.13 Exelixis
      • 7.14 Genmab
      • 7.15 Galaxy Biotech
      • 7.16 GlaxoSmithKline(GSK)
      • 7.17 Hutchison MediPharma
      • 7.18 Johnson & Johnson
      • 7.19 Kringle Pharmaceuticals
      • 7.20 Merck
      • 7.21 Methylgene
      • 7.22 Novartis
      • 7.23 Pfizer
      • 7.24 ProMetic BioTherapeutics
      • 7.25 Takeda Pharmaceutical

      8 C-MET / HGF Inhibitors Manufacturing Cost Analysis

      • 8.1 C-MET / HGF Inhibitors Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of C-MET / HGF Inhibitors
      • 8.4 C-MET / HGF Inhibitors Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 C-MET / HGF Inhibitors Distributors List
      • 9.3 C-MET / HGF Inhibitors Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global C-MET / HGF Inhibitors Market Forecast

      • 11.1 Global C-MET / HGF Inhibitors Production, Revenue Forecast
        • 11.1.1 Global C-MET / HGF Inhibitors Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global C-MET / HGF Inhibitors Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global C-MET / HGF Inhibitors Price and Trend Forecast (2019-2025)
      • 11.2 Global C-MET / HGF Inhibitors Production Forecast by Regions (2019-2025)
        • 11.2.1 North America C-MET / HGF Inhibitors Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe C-MET / HGF Inhibitors Production, Revenue Forecast (2019-2025)
        • 11.2.3 China C-MET / HGF Inhibitors Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan C-MET / HGF Inhibitors Production, Revenue Forecast (2019-2025)
      • 11.3 Global C-MET / HGF Inhibitors Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America C-MET / HGF Inhibitors Consumption Forecast (2019-2025)
        • 11.3.2 Europe C-MET / HGF Inhibitors Consumption Forecast (2019-2025)
        • 11.3.3 China C-MET / HGF Inhibitors Consumption Forecast (2019-2025)
        • 11.3.4 Japan C-MET / HGF Inhibitors Consumption Forecast (2019-2025)
      • 11.4 Global C-MET / HGF Inhibitors Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global C-MET / HGF Inhibitors Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several biological responses collectively known as invasive growth program. These responses are elicited due to activation of several pathways such as RAS pathway, PI3K pathway, STAT pathway, beta-catenin pathway and Notch pathway. However, dysregulation of the HGF/c-MET signaling pathway has been associated with the progression of cancers through activation of oncogenic pathways, angiogenesis and metastasis.
        The major cancers such as breast, colon and non-small-cell lung carcinoma (NSCLC) are being examined for efficacy with c-MET / HGF inhibitors. Several small molecule c-Met kinase inhibitors have demonstrated clinical efficacy in cancer treatment and many clinical trials are underway. However, as the small molecule inhibitors lack specificity or selectivity they can cause toxicity. Therefore, researchers are increasing focus to develop antibody therapeutics against c-Met or HGF.

        The global C-MET / HGF Inhibitors market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on C-MET / HGF Inhibitors volume and value at global level, regional level and company level. From a global perspective, this report represents overall C-MET / HGF Inhibitors market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Abxign
        Abbott Laboratories
        Amgen
        ArQule
        Astex Therapeutics
        AVEO Pharmaceuticals
        Bristol-Myers Squibb(BMS)
        Chroma Therapeutics
        Daiichi Sankyo
        Deciphera Pharmaceuticals
        Eisai
        Eli Lilly
        Exelixis
        Genmab
        Galaxy Biotech
        GlaxoSmithKline(GSK)
        Hutchison MediPharma
        Johnson & Johnson
        Kringle Pharmaceuticals
        Merck
        Methylgene
        Novartis
        Pfizer
        ProMetic BioTherapeutics
        Takeda Pharmaceutical

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        C-Met Biologic Inhibitors
        Small Molecule C-Met Inhibitors
        HGF Antagonist Antibodies
        C-Met Antagonist Antibodies(MetMAb)
        HGF Kringle Variant Antagonists

        Segment by Application
        Hospital Pharmacies
        Retail Pharmacies
        Drug Stores
        Online Sales

        Buy now